Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210 Million
Myriad Genetics agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to Labcorp for $210 million, closing by early 2027.
Myriad Genetics agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to Labcorp for $210 million, closing by early 2027.
Labcorp will buy select BioReference clinical, women’s health, and urology assets from OPKO Health for up to $872 million, adding 80+ patient service centers.
CMS says Medicare pays 16% more than private insurers for lab tests. Preliminary 2027 rates could save $1B a year, with cuts capped at 15%. Craig-Hallum flags code confusion at GeneDx, Adaptive and Myriad, but says the WGS drop looks overdone.
Hims & Hers Health launches lab testing with Quest Diagnostics, offering affordable biomarker tests and personalized health plans as part of its preventive care expansion.